1. SEER: The Surveillance, Epidemiology, and End Results Program (
http://seer.cancer.gov
) – based within the Surveillance Research Program (SRP) at the National Cancer Institute (NCI).
2. Frank, I.N., Graham, S., Jr., Nabors, W.L. (1991) Urologic and Male Genital Cancers. In: Holleb AI, Fink DJ, Murphy GP, editors. Clinical Oncology. Atlanta: American Cancer Society; pp. 280–283.
3. Kessler, B., Albertsen, P. (2003) The natural history of prostate cancer Urol Clin North Am
30, 219–26.
4. Lin, D.W., Noteboom, J.L., Blumenstein, B.A., et al. (1998) Serum percent free prostate-specific antigen in metastatic prostate cancer Urology
52, 366–71.
5. Ploch, N.R., Brawer, M.K. (1994) How to use prostate-specific antigen Urology
43(2), 27–35.